A “weighted” lottery program designed to ensure that people living in the most disadvantaged U.S. neighborhoods would be offered a scarce, potentially life-saving medication proved feasible in a large health system. The approach can improve equity in receipt of the drug by people disproportionately affected by disease, according to an analysis published today in JAMA Health Forum by University of Pittsburgh and UPMC scientist-clinicians.
Scientists at City of Hope have identified a cell metabolism process found in men with diabetes and metastatic prostate cancer that could one day lead to improved testing and treatments for Black men with these diseases.
Researchers at MD Anderson Cancer Center have uncovered a functional role for KRAS mutations in pancreatic cancer and rapidly translated these findings into a novel therapeutic approach combining a KRAS G12D inhibitor with immune checkpoint inhibitors for early- and late-stage KRAS G12D-mutant pancreatic cancer. The combination therapy led to durable tumor elimination and significantly improved survival outcomes in preclinical models, leading to the launch of a phase I clinical trial.
A team of University of Florida medicinal chemists and cancer biologists has created a chemical compound that selectively helps cells dispose of proteins that cause cancer cells to grow.
Radiotheranostics is an approach that involves the use of a single radioactive agent for disease diagnosis and treatment. However, the use of low-molecular-weight proteins and peptides can lead to unwanted accumulation of the associated radioactive metabolites in the kidneys, which interferes with diagnostic accuracy and may cause side effects. Researchers from Japan recently overcame this limitation by developing novel radiolabeled antibody fragments capable of enhancing overall treatment outcomes and imaging accuracy.
City of Hope researchers published preclinical research in Nature Communications demonstrating that a CAR-engineered T-cell therapy worked against ovarian cancer in the laboratory and in preclinical models.
Depression and anxiety are thought to increase a person’s risk of developing cancer, but research results have been inconclusive. In an analysis of multiple studies from the Netherlands, the United Kingdom, Norway, and Canada, investigators found that depression and anxiety are not linked to higher risks for most types of cancer among this population. The analysis is published in Cancer.
Using a novel proteogenomic strategy and a variety of machine learning tools, investigators from the Icahn School of Medicine at Mount Sinai, Fred Hutchinson Cancer Center, and University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer Institute have identified a 64-protein signature that may predict a subset of ovarian cancer patients who are unlikely to respond to chemotherapy.
Loss of a gene known as SYNCRIP in prostate cancer tumors unleashes cellular machinery that creates random mutations throughout the genome that drive resistance to targeted treatments, a team led by UT Southwestern Medical Center researchers discovered. The findings, published in Cancer Cell, could lead to interventions that thwart this process in prostate and other cancer types, making them far easier to treat.
Epstein-Barr virus infection is known to convert resting B lymphocytes into immortal cells that continuously multiply, which leads to posttransplant lymphoproliferative disorder and can evolve to lymphoma and other lymphoproliferative disorders. In a recent study, Japanese researchers discovered the molecular mechanisms of this growth transformation, demonstrating the Epstein-Barr virus induces nucleolar enlargement and increased proliferation in B cells by activating the cancer-related gene IMPDH2.
